Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.
Physician Assistant Program, Duke University Medical Center, Durham, North Carolina; InnAVasc Medical, Inc, Durham, North Carolina.
J Vasc Interv Radiol. 2020 Feb;31(2):243-250. doi: 10.1016/j.jvir.2019.06.010. Epub 2019 Nov 6.
To compare outcomes after conversion of arteriovenous (AV) access to Hemodialysis Reliable Outflow (HeRO) graft vs stent deployment in patients with arm swelling owing to ipsilateral central vein stenosis.
This single-center retrospective study comprised 48 patients (19 men, mean age 58 y) with arm swelling ipsilateral to AV access and central vein stenosis over a 13-year period who had clinical follow-up and without prior central stents. Twenty-one patients underwent placement of a HeRO graft with anastomosis of the HeRO graft to the existing graft or fistula, and 27 patients underwent central venous stent deployment. Symptomatic improvement in arm swelling and access patency rates after intervention were ascertained from medical records.
Improvement in swelling within 1 month after HeRO conversion and stent deployment was found in 95% and 89%, respectively (P = .62). Swelling eventually recurred in 16 patients (59%) treated with stents compared with 1 patient (5%) who underwent HeRO conversion (P < .001). Primary access patency was statistically significantly longer after HeRO conversions than stent deployments, with 6- and 12-month primary patency rates of 89% and 72% vs 47% and 11% (P < .001). HeRO conversions also resulted in longer 6- and 12-month secondary access patency rates (95% and 95% vs 79% and 58%, P = .006). Mean number of interventions per 1,000 access days to maintain secondary patency was 2.7 for the HeRO group vs 6.3 for the stent group.
Although stent deployment and HeRO graft conversion are effective for alleviating arm swelling in the short term in patients receiving hemodialysis with clinically significant arm swelling and functioning AV access, the HeRO graft has more durable results.
比较因同侧中心静脉狭窄导致手臂肿胀而行动静脉(AV)通路转为血液透析可靠流出(HeRO)移植物与支架置入术的患者的转归。
这项单中心回顾性研究纳入了 13 年间因 AV 通路侧手臂肿胀和中心静脉狭窄而就诊且无中心支架置入史的 48 例患者(19 例男性,平均年龄 58 岁),通过病历确定了干预后手臂肿胀和通路通畅率的临床改善情况。21 例患者行 HeRO 移植物置入,将 HeRO 移植物吻合至现有移植物或瘘管;27 例患者行中心静脉支架置入。
HeRO 转归和支架置入后 1 个月内肿胀改善分别见于 95%和 89%的患者(P =.62)。与接受 HeRO 转归的 1 例患者(5%)相比,接受支架治疗的 16 例患者(59%)最终出现肿胀复发(P <.001)。HeRO 转归后通路的初始通畅率明显长于支架置入,6 个月和 12 个月的初始通畅率分别为 89%和 72%与 47%和 11%(P <.001)。HeRO 转归也导致 6 个月和 12 个月的次级通路通畅率更长(95%和 95%与 79%和 58%,P =.006)。维持次级通畅所需的每 1000 个通路日的干预次数,HeRO 组为 2.7,支架组为 6.3。
尽管在有临床意义的手臂肿胀和功能正常的 AV 通路的血液透析患者中,支架置入和 HeRO 移植物转换在短期内均能有效缓解手臂肿胀,但 HeRO 移植物的效果更持久。